NCE-1 Intelligence & Market Opportunity

Brinsupri

Brensocatib

Respiratory Agents

Oral Tablet

Brinsupri is an oral, once-daily dipeptidyl peptidase-1 (DPP1) inhibitor for the treatment of non-cystic fibrosis bronchiectasis (NCFB) in adults and adolescents aged 12 years and older. It represents the first FDA-approved targeted therapy for this chronic, progressive lung disease, directly addressing neutrophil-driven inflammation rather than just symptom management.

Approval Date

12-Aug-25

NCE-1 Date

12-Aug-29

NCE Date

12-Aug-30

Commercial snapshot

Market performance & projections

Revenue ($M)

173

CAGR (%)

121.07%

Projected sales, 2026–2032 ($M)

Analyst projection, $M per year

2026

1,164

2027

2,228

2028

3,186

2029

4,132

2030

5,091

2031

6,030

2032

6,932

Molecule profile

Details & specifications

Molecule

Brensocatib

Innovator

INSMED INC

Dosage Form

Oral Tablet

Strength

10 mg and 25 mg

Therapeutic Category

Respiratory Agents

Usage

To treat non-cystic fibrosis bronchiectasis

Good to know

Frequently asked questions

Ready to act on this opportunity?

Talk to Spring Bio Solution about sourcing, licensing, and filing support for this molecule.

Why Spring Bio Solution

Supported 1000+ clinical trials globally

Provides services across regulatory, legal & clinical research

Unmatched intelligence on batches, expiry, spacing, and historical data from innovators

Integrated CRO services as part of our offerings

Insights on global pricing for smarter clinical trial supply decisions

Global sourcing capability across US, EU, South Africa, Canada, Japan, Australia, New Zealand, Southeast Asia, and other key markets